Recombinant Vaccines Market to Reach USD 25.32 Billion by 2027; Increasing Prevalence of Human Papillomavirus Disease to Brighten Business Prospects, states Fortune Business Insights™

NEXT STORY
Aspero Medical receives $225,000 Grant for development of intraoperative gastrointestinal endoscopic balloon overtube
PREV STORY
Generex Announces Signed Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months

author_avatar
NASDAQ Market News

Kalytera Announces Initiation of Phase 2 Clinical Study in Prevention of Graft Versus Host Disease and Agreement with The Salzman Group of Israel to Manage and Partially Fund the Study to be Led by a World Class Team

SAN FRANCISCO and TEL AVIV, Israel, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, ...

author_avatar
NASDAQ Market News

Gritstone Advances Second Generation COVID-19 Vaccine “CORAL” Program with Support from NIAID; Program has Potential to Protect Against Mutant Variants of SARS-CoV-2

author_avatar
NASDAQ Market News